Neurotoxic protein overexpression disrupts axonal transport, causing inflammation, loss of function, and nerve cell death. These are all hallmarks of neurodegenerative diseases, including Alzheimer's and Parkinson's. Buntanetap, the drug being developed by Annovis, inhibits the production of all the major neurotoxic proteins responsible for AD and PD before they are produced, while other drugs only target one toxic protein after it has already been produced. This novel mechanism of action makes Annovis' drug a potentially effective treatment option for AD and also for PD.
The posters' collective findings highlight a highly promising treatment for neurodegenerative conditions like Alzheimer's disease and Parkinson's disease. First, in mouse models of Alzheimer's disease and other neurodegenerative diseases, buntanetap has been found to inhibit toxic proteins in the brain, enhance axonal transport, reduce inflammation, and safeguard nerve cells from dying. This has been linked to better cognitive function.
Second, these findings have been replicated in all human AD and PD phase I and II trials to date, demonstrating decreased levels of toxic proteins in the brain, improved axonal transport, reduced inflammation, and neuroprotection. In both mice and humans, buntanetap has not only been safe and well-tolerated but has also improved movement in PD trials and cognition in AD trials. Additionally, in mice and humans, evidence shows a dose-response relationship between drug dose and inhibition of neurotoxic proteins. Currently in phase III trials,
In “Do Mouse Data Lie? For Buntanetap, Mouse Data Are Predictive Of Humans” - Annovis conducted a study to see if the data collected from animals would resemble the data collected from humans. Through their research on Alzheimer's disease in mouse models and humans, they were able to reduce the production levels of toxic proteins from disease levels to normal levels. The results consistently showed lower levels of neurotoxic aggregating proteins and significant improvements in cognition after buntanetap treatment.
“It is very exciting to have concordance of results from animal and human studies combined with the human trials being on track with our once daily oral medication yielding no drug-related serious adverse events, low drop out rate and minimal adverse effects,” said
The CTAD conference is a gathering that brings together key leaders in Alzheimer's Disease research from both industry and academia to form partnerships with the goal of accelerating the development of effective treatments to combat the disease.
Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words, and include, without limitation, statements regarding the timing, effectiveness, and anticipated results of buntanetap clinical trials. Forward-looking statements are based on
Back to Top